肿瘤防治研究2025，Vol.52Issue(2)：103-109,7.DOI:10.3971/j.issn.1000-8578.2025.24.0856
河北省晚期食管鳞癌免疫治疗现状及进展
Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province
段晓阳 1史健1
作者信息
- 1. 050011 石家庄,河北医科大学第四医院肿瘤内科
- 折叠
摘要
Abstract
Esophageal squamous cell carcinoma(ESCC)is one of the most prevalent gastrointestinal cancers in Hebei province.Most patients are diagnosed at an advanced stage due to untypical early symptoms,making surgical treatment often unfeasible.As a result,most of them are treated with comprehensive medical treatment,which tends to have limited effectiveness and poor prognosis.However,the recent introduction of immunotherapy has considerably advanced treatment options for patients with advanced ESCC,notably improving their prognosis.Uncertainties regarding immune resistance,the selection of predictive indicators of efficacy,the identification of dominant population,and the choice of combined treatment strategies are still evident.Therefore,based on the high incidence and poor prognosis of ESCC in Hebei Province,this article will briefly review the research progress in the treatment of advanced ESCC,aiming to provide guidance for treatment strategies for advanced esophageal cancer.关键词
食管鳞状细胞癌/免疫治疗/研究进展Key words
Esophageal squamous cell carcinoma/Immunotherapy/Research progress分类
临床医学引用本文复制引用
段晓阳,史健..河北省晚期食管鳞癌免疫治疗现状及进展[J].肿瘤防治研究,2025,52(2):103-109,7.
